Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.…

Bristol-Myers Squibb stock slips despite earnings beat By Investing.com

Bristol-Myers Squibb stock slips despite earnings beat…

Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates By Investing.com

Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates…

Bristol Myers posts quarterly loss, revenue rises 5%

Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio…

Pharmabranche: Neuer Novartis-Chef kommt von Bristol Myers Squibb

Jörg Reinhardt tritt nach zwölf Jahren als Novartis-Chef zurück. Sein Nachfolger steht bereits fest. Er kommt von einem direkten Konkurrenten.…

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…

Is Bristol Myers Squibb A Buy At These Bottom Levels?

…

Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies By Reuters

Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies…

Got $500? 3 Healthcare Stocks to Buy and Hold Forever

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…

Got $500? 3 Healthcare Stocks to Buy and Hold Forever @themotleyfool #stocks $ISRG $BMY $NVO

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…

Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%

The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…

Biotech im Visier - Bristol-Myers Squibb, Formycon, MorphoSys, Vidac Pharma Aktie

Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg…

Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? @themotleyfool #stocks $BMY $LLY $^GSPC $NVO $VOO

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…

Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…

Global Chemotherapy Market Size To Exceed USD 16.2 Billion By 2033 | CAGR of 6.54%

The Global Chemotherapy Market Size was Valued at USD 8.6 Billion in 2023 and the Worldwide Chemotherapy Market Size is…

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent - diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Bristol Myers Squibb: The Comeback Is Unfolding

…

Is Bristol Myers Squibb Stock a Buy?

The company is going through a rough patch.…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Bristol-Myers Squibb Is Not A Buy For Me

…

Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com

Bristol Myers Squibb completes Karuna Therapeutics buyout…

Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)

…

Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com

Karuna Therapeutics set to merge with Bristol-Myers Squibb…

Bristol-Myers Squibb: Großes Interesse an ADC-Playern - Tubulis holt hochkarätige Investoren an Bord - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…